Dyne Therapeutics (NASDAQ:DYN) Director Brian Posner Acquires 2,500 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner bought 2,500 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $17.12 per share, for a total transaction of $42,800.00. Following the completion of the transaction, the director owned 18,000 shares in the company, valued at approximately $308,160. The trade was a 16.13% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $17.37 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The stock’s 50-day moving average is $18.28 and its two-hundred day moving average is $18.39. The firm has a market cap of $2.87 billion, a P/E ratio of -5.39 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period last year, the business earned ($1.05) earnings per share. Analysts predict that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DYN has been the topic of several research reports. Morgan Stanley dropped their target price on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Evercore set a $33.00 target price on Dyne Therapeutics in a research report on Friday, May 15th. HC Wainwright dropped their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Finally, Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Institutional Trading of Dyne Therapeutics

Large investors have recently made changes to their positions in the stock. Hilton Head Capital Partners LLC bought a new stake in shares of Dyne Therapeutics during the 1st quarter worth about $26,000. Chung Wu Investment Group LLC bought a new stake in shares of Dyne Therapeutics during the 3rd quarter worth about $30,000. Strs Ohio bought a new stake in shares of Dyne Therapeutics during the 4th quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Dyne Therapeutics by 25.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after acquiring an additional 1,109 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Dyne Therapeutics during the 4th quarter worth about $84,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.